On Thursday, Thailand detected the first new variant of monkeypox in Asia. After the news was released, monkeypox therapy developers in the US stock market generally rose in early trading on Thursday.
According to Zhītōng Finance, on Thursday, Thailand detected the first new variant of monkeypox in Asia. After the news was released, monkeypox therapy developers in the US stock market generally rose in early trading on Thursday. T2 Biosystems (TTOO.US) and GeoVax Labs (GOVX) rose more than 2%, while Tonix Pharmaceuticals (TNXP.US) rose more than 1%.
The Department of Disease Control in Thailand's Ministry of Health announced that the patient who tested positive for the Ib strain is a European male who arrived in Bangkok from Africa last week. Authorities have identified 43 close contacts of the patient and are monitoring them. The patient, who had symptoms related to monkeypox, was hospitalized on August 15, the second day after arriving in Bangkok. The department stated that Thursday's laboratory test confirmed the variant as the Ib strain.
Monkeypox is a zoonotic disease caused by monkeypox virus infection, which can cause fever, pain, and skin pustule lesions. It has previously mainly occurred in Central Africa and West Africa, and is mainly transmitted through sexual contact in humans. This is the second time in more than two years that WHO has declared a monkeypox epidemic to be an "international public health emergency." The monkeypox outbreak was also triggered from Congo. A new variant of monkeypox virus type Ib first appeared in September 2023 and has now been found for the first time outside Congo. This new variant strain of monkeypox virus is different from the type II monkeypox virus popular in the second half of 2022 and has a higher mortality rate.